PROK vs. DNAB, DNAD, VPCB, FLYA, LGST, VERA, HRMY, ZLAB, MIRM, and NTLA
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Social Capital Suvretta Holdings Corp. II (DNAB), Social Capital Suvretta Holdings Corp. IV (DNAD), VPC Impact Acquisition Holdings II (VPCB), SOAR Technology Acquisition (FLYA), Semper Paratus Acquisition (LGST), Vera Therapeutics (VERA), Harmony Biosciences (HRMY), Zai Lab (ZLAB), Mirum Pharmaceuticals (MIRM), and Intellia Therapeutics (NTLA).
ProKidney (NASDAQ:PROK) and Social Capital Suvretta Holdings Corp. II (NASDAQ:DNAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.
ProKidney's return on equity of 0.00% beat Social Capital Suvretta Holdings Corp. II's return on equity.
ProKidney has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Social Capital Suvretta Holdings Corp. II has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.
ProKidney currently has a consensus target price of $4.00, suggesting a potential upside of 71.67%. Given ProKidney's higher possible upside, research analysts clearly believe ProKidney is more favorable than Social Capital Suvretta Holdings Corp. II.
ProKidney received 7 more outperform votes than Social Capital Suvretta Holdings Corp. II when rated by MarketBeat users.
51.6% of ProKidney shares are held by institutional investors. Comparatively, 76.6% of Social Capital Suvretta Holdings Corp. II shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, ProKidney had 12 more articles in the media than Social Capital Suvretta Holdings Corp. II. MarketBeat recorded 12 mentions for ProKidney and 0 mentions for Social Capital Suvretta Holdings Corp. II. ProKidney's average media sentiment score of 0.22 beat Social Capital Suvretta Holdings Corp. II's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.
Summary
ProKidney beats Social Capital Suvretta Holdings Corp. II on 8 of the 11 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
